clinical trial

[Hope Biosciences Stem Cell Research Foundation (BusinessWire, Inc.)] Non-profit research organization Hope Biosciences Stem Cell Research Foundation has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis.

[Palisade Bio, Inc.] Palisade Bio, Inc. and co-development partner Newsoara announced positive topline Phase II clinical trial data that LB1148 had a statistically significant effect in accelerating the return of bowel function in patients undergoing elective bowel resection surgery.

[Stemson Therapeutics] Stemson Therapeutics announced the closing of a $15 million Series A financing to advance development of Stemson’s proprietary therapeutic solution to cure hair loss. Stemson’s iPSC based technology is capable of producing the cell types required to initiate hair follicle growth and have been successfully tested in small animal models.

[Kronos Bio, Inc.] Kronos Bio, Inc. announced the US FDA has cleared its Investigational New Drug Application for LANRA, allowing the company to proceed with a Phase I/II clinical trial of LANRA in patients with relapsed or refractory FLT3-mutated AML in combination with gilteritinib.

[Leukemia] In this Phase I/II clinical trial, the authors investigated the safety and efficacy of high doses of mb-IL21 ex vivo expanded donor-derived NK cells to decrease relapse in 25 patients with myeloid malignancies receiving haploidentical stem-cell transplantation.

[PolarityTE, Inc.] PolarityTE, Inc. announced the submission of an investigational new drug application to the US FDA seeking authorization to commence a clinical trial to evaluate its SkinTE product for the proposed indication of treatment of chronic cutaneous ulcers.